Q4 launch of TranscripTx™ genetic test

AI SummaryClose X

Verici Dx Plc announced the upcoming Q4 2026 launch of TranscripTx™, a novel genetic test for organ transplant patients utilizing next-generation sequencing and AI-enabled gene selection. This laboratory-developed test, offered through Verici's CLIA-certified laboratory, measures genetic variants in peripheral blood RNA to identify polymorphisms that influence transplant recipient response to therapy and long-term graft failure risk. TranscripTx™ is positioned as the only multi-gene panel specifically developed for transplant recipients and can detect splice variants beyond the capabilities of cell-free DNA technologies, leveraging the company's extensive data repository to advance precision medicine in transplantation.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings